Stock Events

Stock Events

VolitionRX 

$2.59
27
-$0.07-2.59% Today

Statistics

Day High
2.9
Day Low
2.57
52W High
18.4
52W Low
2
Volume
227,586
Avg. Volume
-
Mkt Cap
318.19M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

19AugExpected
Q2 2024
Q3 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Next
-0.97
-0.66
-0.35
-0.04
Expected EPS
-0.648
Actual EPS
N/A

Financials

-2,185.41%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
2.47MRevenue
-53.94MNet Income

Analyst Ratings

2.00Average Price Target
The highest estimate is 3.00.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow VNRX. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Guardant Health
GH
Mkt Cap17.2B
Guardant Health, Inc. specializes in liquid biopsy tests, a similar market niche to VolitionRX's blood-based cancer detection tests.
Grifols SA
GRFS
Mkt Cap5.34B
Grifols, S.A. provides a range of diagnostic solutions, including for cancer, competing in the broader diagnostic market alongside VolitionRX.
Qiagen NV
QGEN
Mkt Cap7.55B
Qiagen N.V. offers molecular diagnostics and sample preparation technologies, competing in the cancer diagnostics and research market.
Fulgent Genetics
FLGT
Mkt Cap515.19M
Fulgent Genetics, Inc. provides comprehensive genetic testing solutions, competing in the genomic and molecular diagnostics space.
Pacific Biosciences of California
PACB
Mkt Cap462.8M
Pacific Biosciences of California, Inc. develops sequencing systems, indirectly competing by advancing cancer research and potentially diagnostics.
Illumina
ILMN
Mkt Cap24.66B
Illumina, Inc. provides sequencing and array-based solutions for genetic analysis, competing in the broader genomics and diagnostics market.
TG Therapeutics
TGTX
Mkt Cap5.81B
TG Therapeutics, Inc. focuses on developing treatments for B-cell malignancies and autoimmune diseases, indirectly competing by targeting cancer treatment and diagnosis.

About

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. It sells Nu.Q that detect cancer; Nu.Q Nets, monitoring the immune system; Nu.Q Vet cancer screening test for veterinary applications; Nu.Q Capture capturing and concentrating samples for more accurate diagnosis; and Nu.Q Discover, a solution to profiling nucleosomes. The company operates Nucleosomics a technology platform for blood test. VolitionRx Limited is based in Austin, Texas.
Show more...
CEO
Mr. Cameron Reynolds MBA
Employees
85
Country
United States
ISIN
US9286612067

Listings

XASE
US
VNRX
BOATS
BOATS
VNRX.BOATS

0 Comments

Share your thoughts

FAQ

What is VolitionRX stock price today?▼
The current price of VNRX is $2.59 USD — it has decreased by -2.59% in the past 24 hours. Watch VolitionRX stock price performance more closely on the chart.
What is VolitionRX stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange VolitionRX stocks are traded under the ticker VNRX.
Is VolitionRX stock price growing?▼
VNRX stock has fallen by -11.04% compared to the previous week, the month change is a +8.35% rise, over the last year VolitionRX has showed a -74.8% decrease.
What is VolitionRX market cap?▼
Today VolitionRX has the market capitalization of 318.19M
When is the next VolitionRX earnings date?▼
VolitionRX is going to release the next earnings report on August 19, 2026.
What were VolitionRX earnings last quarter?▼
VNRX earnings for the last quarter are -0.97 USD per share, whereas the estimation was -0.73 USD resulting in a -32.88% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is VolitionRX revenue for the last year?▼
VolitionRX revenue for the last year amounts to 2.47M USD.
What is VolitionRX net income for the last year?▼
VNRX net income for the last year is -53.94M USD.
How many employees does VolitionRX have?▼
As of June 02, 2026, the company has 85 employees.
In which sector is VolitionRX located?▼
VolitionRX operates in the Health & Wellness sector.
When did VolitionRX complete a stock split?▼
The last stock split for VolitionRX was on April 28, 2026 with a ratio of 1:20.
Where is VolitionRX headquartered?▼
VolitionRX is headquartered in Henderson, United States.